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Summary
Tamoxifen, a triphenylethyleneestrogen receptor modulator, is an eff ective treatment for estrogen receptor positive 
breast cancer patients. It acts as an estrogen antagonist in breast tissue and a week estrogen agonist in the female genital 
tract. Its estrogenagonist properties refl ects on increased risk of gynaecologic pathologies and includes the development of 
endometrial cancer, endometrial hyperplasia, endometrial polyps, adenomyosis, leiomyomas, uterine sarcomas, cervical 
polyps and ovarian cysts. Breast cancer patients during tamoxifen treatment should be under close gynaecological and ul-
trasonographic surveillance.
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UČINAK TAMOXIFEN NA ŽENSKI REPRODUKTIVNI SUSTAV
Sažetak
Tamoxifen, trifeniletilenski modulator estrogesnih receptora, se koristi u liječenju raka dojke s pozitvnim estrogenskim 
receptorima. U tkivu dojke i tumorskim stanica ima estrogen-antagonistički učinak, a u ženskom spolnom sustavu blagi 
agonistički učinak što se očituje povećanim rizikom od ginekoloških bolesti koje uključuju rak endometrija, hiperplaziju 
endometrija, polipe endometrija, adenomiozu, miome, sarkome, polipe vrata maternice i ciste jajnika. Bolesnice s rakom 
dojke koje se liječe tamoxifenom trebaju biti redovito ginekološki i ultrazvučno pregledavane.
KLJUČNE RIJEČI: tamoxifen, rak dojke, ženski spolni sustav, rak endometrija
INTRODUCTION
Tamoxifen, a triphenylethyleneestrogen re-
ceptor modulator, is an eff ective treatment for es-
trogen receptor (ER) positive breast cancer pa-
tients. It has been conclusively demonstrated to 
reduce the risk of breast cancer recurrence in 
women with ER positive breast cancer by binding 
to ERs and blocking tumor proliferation (1). 
Tamoxifen treatment for 5 years reduces the rate 
of recurrence during the treatment and through-
out the fi rst decade after diagnosis and reduces 
breast cancer mortality rate by a third throughout 
the fi rst 15 years after diagnosis (2). Prophylactic 
use of tamoxifen reduces the incidence of ER-pos-
itive breast cancer in healthy women for 45 % (3).
The side eff ects of tamoxifen are diverse and 
related to its mechanism of action, with mixed 
agonistic/antagonistic eff ects on various tissues. 
Its oestrogen-agonist properties refl ects on in-
creased risk of gynaecologicpathologies and in-
cludes the development of endometrial cancer, 
endometrial hyperplasia, endometrial polyps, ad-
enomyosis, leiomyomas, uterine sarcomas, cervi-
cal polyps and ovarian cysts (3,4).
Tamoxifen is listed as human carcinogen 
since 1996.
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GYNAECOLOGICAL CHANGES 
IN PREMENOPAUSAL BREAST CANCER 
PATIENTS RECEIVING TAMOXIFEN
The tamoxifen eff ects on female genital tract 
varies with the serum estradiol (E2) concentration 
and hence menopausal status of the patient (5,6). 
Clinical data indicate that tamoxifen therapy do 
not increased risk of endometrial pathology in 
premenopausal patients (3). Premenopausal wo-
men with continued ovarian activity and therefore 
elevated serum E2 levels have a litt le, or no risk of 
tamoxifen causing uterine cancer (2,3). In pros-
pective study Cheng et al. detected no diff erences 
in mean endometrial thickness and histopatho-
logic fi ndings in premenopausal symptomatic pa-
tients, regardless of tamoxifen ingestion and con-
cluded that tamoxifen might be associated with 
premalignant or malignant changes of endome-
trium only in symptomatic postmenopausal wo-
men (7). In their study, in premenopausal women 
using tamoxifen endometrial thickness was not 
increased.Chang et al. reported that patients who 
became amenorrheic during long-term tamoxifen 
treatment with low serum E2 levels have increased 
endometrial thickness on ultrasound, increased 
frequency of endometrial pathology and may be 
at special risk of endometrial cancer (8). Tamoxi-
fen, in amenorrheic women with low serum E2 
levels, causes endometrial thickening and in 
women with elevated serum E2 levels has an op-
posite antiestrogenic eff ect (8). Chen et al. in their 
retrospective cohort study including 74,280 ta-
moxifen treated breast cancer patients concluded 
that tamoxifen use for more than three years and/
or patients older than 35 years have signifi cantly 
increased risk for developing endometrial cancer 
(9). This study obtained several unique fi ndings 
that are not in accordance with previous studies. 
Increased endometrial cancer risk was usually re-
ported after 5-year tamoxifen use (10,11) and in 
accordance with menopausal status as mentioned 
above (2,7,9). Pateinetage (>35 years) became an 
important risk factor for the development of endo-
metrial cancer in tamoxifen treated breast cancer 
patients.
Formation of ovarian cysts in breast cancer 
patients during tamoxifen treatment has also been 
reported (3,12). Mourits et al. in cross-sectional 
study reported that ovarian cysts in tamoxifen 
treated breast cancer patients develop only if ova-
ries are able to respond to tamoxifen by E2 pro-
duction (13). In premenopausal women tamoxifen 
disrupts menstrual cycle by increasing the level of 
gonadotropin releasing hormone which stimu-
lates ovarian estrogens production resulting in el-
evated E2 levels (3). Patients with menstrual peri-
ods during tamoxifen treatment usually develop 
simple ovarian cysts, follicular cysts, luteinized 
follicular cysts and corpus luteum cystswith re-
ported incidence of 40-81% (3,13). These cysts dis-
appeared in time or after cessation of tamoxifen 
therapy requiring no surgical intervention if not 
complicated by torsion (13). Powles et al. in a pla-
cebo-controlled tamoxifen trial reported signifi -
cant increase in hot fl ushes mostly in premeno-
pausal women, vaginal discharge, menstrual ir-
regularities and increased incidence of benign 
ovarian cysts (14).
GYNAECOLOGICAL CHANGES 
IN POSTMENOPAUSAL BREAST CANCER 
PATIENTS RECEIVING TAMOXIFEN
The increased risk of endometrial cancer and 
benign uterine alterations has been reported for 
postmenopausal women associated with long 
term tamoxifen treatment (3,9,15). Tamoxifen is an 
estrogen agonist in the female genital tract in post-
menopausal women. Deligdisch et al. evaluated 
endometrial histopathologic fi ndings from 700 
breast cancer patients treated with tamoxifen and 
found endometrial polyps, hyperplasia and can-
cer in one-third of all patients (16). These side ef-
fects are related to tamoxifen ability to stimulate 
proliferation of endometrium (4). Endometrial 
polyps occur in 8-50% of breast cancer patients 
treated with tamoxifen (3,16-18). Such polyps dif-
fer histologically from endometrial polypsof 
healthy patients not receiving tamoxifen and have 
more often (10-20 fold) malignant changes (3). 
Deligdisch et al. found 15 of 33 endometrial can-
cers in endometrial polyps (16). Endometrial hy-
perplasia occurs in 16-50% of breast cancer pa-
tients treated with tamoxifen (3,16-18). If endome-
trial atypical hyperplasia or endometrial complex 
hyperplasia without atypia is present cessation of 
tamoxifen therapy is advisable and if not, hyster-
ectomy may be an option (3).Tamoxifen use in-
creases the risk of endometrial cancer by 2 to 4 
fold with overall incidence of 1.6-3.0 per 1000 
tamoxifen treated breast cancer patients (2,3,19). 
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Van Leeuwen et al (20) reported that women who 
had used tamoxifen for more than 2 years had 
greater risk of endometrial cancer than never us-
ers. There was a signifi cant trend of increasing 
risk of endometrial cancer with duration of tamox-
ifen use and also with cumulative dose (20). There 
is no diff erence in histologic phenotypes or prog-
nostic factors of endometrial cancers found in 
tamoxifen treated patients from those of patients 
not receiving tamoxifen.In breast cancer patient 
with planned tamoxifen therapy pre-treatment-
transvaginal ultrasonography screening is recom-
mended to reveal high-risk group of patients with 
endometrial thickening. Transvaginal ultrasonog-
raphy is also used to triage tamoxifen treated 
breast cancer patients. Standard, accepted endo-
metrial thickness cut-off  point is 5 mm in post-
menopausal women, but with low frequency of 
signifi cant fi ndings on hysteroscopy. Love et al. 
recommended endometrial thickness cut-off  point 
of 8 mm in asymptomatic tamoxifen treated breast 
cancer patients (21). Seoud et al. found that all pa-
tients with an abnormal endometrium had abnor-
mal vaginal bleeding with no correlation between 
endometrial thickness and endometrial pathology 
and concluded that the value of routine ultraso-
nography screening for endometrial pathology is 
controversial (22). Endometrial sampling should 
always be obtained in symptomatic patients.
In addition, tamoxifen treatment is signifi -
cantly associated with appearance of uterine sar-
coma (especially MMMTs), endometrial stromal 
sarcomas, adenofi bromas, cervical polyps, devel-
opment of endometriosis and with growth of leio-
myomasin postmenopausal breast cancer patients 
(3). The relationship between tamoxifen use and 
cervical cancer and vaginal neoplasms has not 
been reported in literature (3). There is no consen-
sus whether postmenopausal breast cancer tamox-
ifen users risk developing ovarian cancer. Regard-
less of tamoxifen treatment, these patients have 
increased risk to develop ovarian tumorsdue to 
genetic factors (23).
The benefi ts of tamoxifentherapy are still 
without debate, despite possible severe side ef-
fects of this drug.
CONCLUSION
Breast cancer patients during tamoxifen treat-
ment should be under close gynecological andul-
trasonographic surveillance. It is recommended 
that all tamoxifen treated breast cancer patients 
(premenopausal and postmenopausal) should un-
dergo gynaecological and transvaginal ultrasono-
graphic examination every 4-6 months or at least 
annually. Endometrial sampling should be ob-
tained when the endometrium is thickened or in 
the event of abnormal uterine bleeding or vaginal 
discharge.
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